Atlas Venture
http://www.atlasventure.com/Atlas Venture is a venture capital firm that invests in early stage technology and life sciences businesses. Since the firm’s founding in 1980, the firm has helped build over three hundred companies. Since 1995, forty seven of its investments have been acquired and more than forty have gone public, with an aggregate market capitalization of over $20 billion.
View Older Stories View More Recent Stories
-
Form 13F-HR Atlas Venture Associates For: Mar 31
-
Form 13F-NT ATLAS VENTURE FUND VI For: Mar 31
-
Form 13F-HR Atlas Venture Advisors, For: Mar 31
-
Form 13F-NT Atlas Venture Associates For: Mar 31
-
Form 13F-NT Atlas Venture Associates For: Mar 31
-
Cadent Therapeutics Closes $15 Million Final Equity Tranche of Series B Financing
-
Accent Therapeutics Announces $63 Million Series B Financing to Advance Novel, Precision Cancer Therapies Targeting RNA-Modifying Proteins
-
Affinia Therapeutics Raises $60M in Series A Financing to Advance Rational Design AAV Platform and Transformative Gene Therapies
-
Affinia Therapeutics Raises $60M in Series A Financing to Advance Rational Design AAV Platform and Transformative Gene Therapies
-
Dyne Therapeutics Announces Equity Investment from CureDuchenne Ventures to Support Pioneering Approach to Restoring Muscle Health in DMD
-
Kymera Therapeutics Announces $102 Million Series C Financing to Advance its Protein Degrader Pipeline and Platform
-
Cadent Therapeutics Announces FDA Clearance of IND Application and Dosing of Subjects of CAD-9303 for Schizophrenia
-
Obsidian Therapeutics Appoints Anders Götzsche to Board of Directors
-
Akrevia Therapeutics Rebrands as Xilio Therapeutics and Announces $100.5 Million Series B Financing
-
Cadent Therapeutics to Present at the Cowen 40th Annual Health Care Conference
-
Triplet Therapeutics to Present at Cowen 40th Annual Health Care Conference
-
Cadent Therapeutics to Present at the 9th Annual SVB Leerink Global Healthcare Conference
-
Form 4 AVROBIO, Inc. For: Feb 13 Filed by: ATLAS VENTURE ASSOCIATES X, L.P.
-
Form SC 13G/A Magenta Therapeutics, Filed by: Atlas Venture Fund X, L.P.
-
Form SC 13G Akero Therapeutics, Inc. Filed by: Atlas Venture Fund XI, L.P.
-
Form 13F-NT ATLAS VENTURE FUND VI For: Dec 31
-
Form 13F-NT Atlas Venture Associates For: Dec 31
-
Form 13F-NT Atlas Venture Associates For: Dec 31
-
Form 13F-HR Atlas Venture Advisors, For: Dec 31
-
Form 13F-HR Atlas Venture Associates For: Dec 31
-
Form 4 Akero Therapeutics, Inc. For: Feb 07 Filed by: Atlas Venture Opportunity Fund I, L.P.
-
Cadent Therapeutics Announces Poster Presentation at the 3rd Pan American Parkinson’s Disease and Movement Disorders Congress
-
Dyne Therapeutics Expands Leadership Team with Key Hires
-
Form SC 13G/A Translate Bio, Inc. Filed by: Atlas Venture Fund VIII, L.P.
-
Form SC 13G BICYCLE THERAPEUTICS Filed by: Atlas Venture Fund VIII, L.P.
-
Form SC 13G/A ZAFGEN, INC. Filed by: Atlas Venture Fund VII L P
-
Form SC 13G/A Unum Therapeutics Inc. Filed by: Atlas Venture Fund IX, L.P.
-
Form SC 13G/A Surface Oncology, Inc. Filed by: Atlas Venture Fund IX, L.P.
-
Form SC 13G/A Spero Therapeutics, Inc. Filed by: Atlas Venture Fund IX, L.P.
-
Ikena Oncology Announces Dosing of First Patient in Phase 1 Study Evaluating IK-175 in Patients with Advanced Solid Tumors
-
Arix Co-founds Quench Bio With Series A Financing
-
Quench Bio Closes $50M Series A Financing to Advance First-in-Class Medicines Targeting Gasdermin to Treat Severe Inflammatory Diseases
-
Cadent Therapeutics Announces FDA Acceptance of IND Application for CAD-1883 for Spinocerebellar Ataxia (SCA)
-
Disarm Therapeutics Appoints Veteran Biotech Executive Scott Holmes as Chief Financial Officer
-
Generation Bio to Present at 38th Annual J.P. Morgan Healthcare Conference
-
Generation Bio Announces $110 Million Series C Financing to Advance Lead Programs for Hemophilia A and PKU
-
Karl Naegler joins Wellington Partners as Managing Partner
-
Form 4 Akero Therapeutics, Inc. For: Dec 31 Filed by: Atlas Venture Fund XI, L.P.
-
Form 4 Akero Therapeutics, Inc. For: Dec 17 Filed by: Atlas Venture Fund XI, L.P.
-
Indalo Therapeutics Appoints Healthcare Industry Veteran and Serial Entrepreneur Michael Heffernan as Board Chair
-
Triplet Therapeutics Launches with $59 Million in Financing to Further its Development of Transformative Treatments for Triplet Repeat Disorders
-
Cadent Therapeutics Announces Poster Presentation at the 2019 Annual Meeting of the American College of Neuropsychopharmacology (ACNP)
-
Kyn Therapeutics Rebrands as Ikena Oncology, Reflecting Next Phase of Growth
-
Cadent Therapeutics to Present at the Piper Jaffray 31st Annual Healthcare Conference
-
IFM Therapeutics Announces $55.5 Million Financing to Launch and Fund New Subsidiaries and Appointment of Dr. H. Martin Seidel as Chief Executive Officer

